Fundz
Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every contract, funding round, exec hire, and M&A move on BetterLife Pharma — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plansBook a 15-min walkthrough
Watch the 2-minute tour · with sound

BetterLife Announces Closing of a Private Placement for BETR-001 and BETR-002 Compounds

Jul 02, 2024almost 2 years ago

Contract Type

partnership

VancouverBiotechnology

Description

BetterLife Pharma Inc. announced the closing of a non-brokered private placement, pursuant to which the Company issued 1,750,000 units at a price of $0.10 per Unit for aggregate gross proceeds of $175,000. The company primarily focuses on developing and commercializing BETR-001 and BETR-002 compounds to treat neuro-psychiatric and neurological disorders.

Company Information

Company

BetterLife Pharma

Location

Vancouver, British Columbia, Canada

About

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.

Predictive Intelligence
Strategic

ML-powered predictions for BetterLife Pharma's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months